Tekmira Pharmaceuticals

  • Tekmira Pharmaceuticals
    Tekmira Pharmaceuticals
Previous Next

Tekmira Pharmaceuticals

Turning a Healthcare Merger into a New Leader in Hepatitis B


Close to finalizing a cross-border merger that would completely transform Tekmira Pharmaceuticals, the company asked Edelman: how do we help the investment community see the same opportunity that we do? We recognized a chance to craft a story that would secure shareholder support and reposition Tekmira in a new segment.

Tekmira Pharmaceuticals


On the first day of the world’s premier healthcare investor conference, Tekmira and OnCore Biopharma announced a $750-million-merger, creating a leading global biotechnology company focused on developing a cure for hepatitis B.

To effectively tell that story, we built a narrative and communications strategy aimed at winning shareholder support. Additionally, we managed media relations and produced a range of materials that would inform employees, the industry, and other critical stakeholders.


Within three months, 99.5 per cent of Tekmira’s shareholders voted in favour of the transaction. Today, the combined company, rebranded as Arbutus Biopharma, is advancing towards a curative regimen for a debilitating and deadly disease that infects roughly 350 million people globally.